Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data on promising investigational treatment for metastatic breast cancer reviewed
December 8th, 2005
Encouraging response rates have been achieved in women with advanced breast cancer treated with the investigational drug lapatinib, according to a recently published review. The early results shown by lapatinib are reviewed in the journal Core Evidence, the first international peer-reviewed publication to assess medications by critically evaluating evidence on clinical effectiveness and outcomes. Breast cancer is the most common cancer affecting women, with approximately 40,000 deaths each year in the US despite advances in detection and treatment. Metastatic disease represents the biggest clinical challenge, with a median survival time of 2...
Source: Women's Health Weekly (2005-12-08)
|
